MARKET

LSTA

LSTA

Lisata Therapeutics Inc
NASDAQ
2.895
+0.095
+3.39%
Opening 13:05 07/09 EDT
OPEN
2.740
PREV CLOSE
2.800
HIGH
2.950
LOW
2.653
VOLUME
34.14K
TURNOVER
--
52 WEEK HIGH
4.200
52 WEEK LOW
1.870
MARKET CAP
24.89M
P/E (TTM)
-1.2598
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LSTA last week (0630-0704)?
Weekly Report · 2d ago
H.C. Wainwright Keeps Their Buy Rating on Lisata Therapeutics (LSTA)
TipRanks · 07/02 17:15
Weekly Report: what happened at LSTA last week (0623-0627)?
Weekly Report · 06/30 10:32
Lisata Therapeutics Reveals Promising Phase 2 Trial Data
TipRanks · 06/26 12:54
Lisata Therapeutics announces preliminary cohort B results from ASCEND trial
TipRanks · 06/26 12:11
AGITG, NHMRC Clinical Trials Centre At University Of Sydney, And Lisata Therapeutics Announce Preliminary Cohort B Data From ASCEND Phase 2b Trial In Metastatic Pancreatic Cancer
Benzinga · 06/26 12:07
LISATA THERAPEUTICS - 6MPFS OF 60.8% FOR CERTEPETIDE-TREATED GROUP VS 25% FOR PLACEBO IN DATA FROM COHORT B
Reuters · 06/26 12:00
Weekly Report: what happened at LSTA last week (0616-0620)?
Weekly Report · 06/23 10:27
More
About LSTA
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.

Webull offers Lisata Therapeutics Inc stock information, including NASDAQ: LSTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LSTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LSTA stock methods without spending real money on the virtual paper trading platform.